You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Software as a Service Cardiovascular PACS Based on Web 2.0 Technologies
SBC: HEART IMAGING TECHNOLOGIES, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Nearly two-thirds of all medical imaging procedures in the United States are performed in physician offices, yet few of these small healthcare providers can afford picture archiving and communication systems (PACS) needed to exchange these images with large hospitals. Without online access to previous imaging tests many procedures are repeated, leading to exces ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Proteolytic Imaging of Remodeling Myocardium
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bioethical Considerations for Building, Evaluating, and Implementing Artificial Intelligence in Perinatal Mood and Anxiety Disorders
SBC: Iris OB Health Inc. Topic: 104PROJECT SUMMARY Postpartum depression (PPD) is a common, yet treatable illness if detected early, but it can also have deleterious effects to the mother and child if left untreated. Routine screening for PPD is considered best practice but does not consistently occur due to time and resource constraints. As a result, therapeutic interventions are initiated late and many PPD cases go undetected alt ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Cell therapy of diabetes using broad spectrum multipotent stem cells
SBC: PLUREON CORP. Topic: N/ADESCRIPTION (provided by applicant): Transplantation of insulin-producing cells in many diabetes patients potentially would restore normal glucose homeostasis and prevent the severe long-term complications of the disease. However, the scarcity of donated pancreata currently limits transplantation of the whole organ or of isolated pancreatic islets to a tiny fraction of those patients who might ben ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
A Precision Medicine for Alcohol-Associated Liver Disease
SBC: GENETOBE INC Topic: 150ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-Induced Hypothermia
SBC: HALIMED PHARMACEUTICALS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. In spite of intensive investigations, clinical therapies for treating acute stroke patients remain limited and unsatisfactory. There are consistent animal and human data that mild to moderate hypothermia (reducing body temperature to 32-34oC) is generally safe and improves outcome after brain ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Delivery of chemically modified PNA oligomers
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Discovery of Novel Drugs for Autism
SBC: ASDDR, LLC Topic: 101Summary The goal of this study is to discover novelmechanism based pharmacological intervention for autisma devastating neurodevelopmental disorder with no treatment currentlyGenetic sequencing has revealed extensive overlap in risk genes for autism and for cancermany of which are chromatin remodeling factors important for transcriptional regulationsuggesting the possibility of repurposing the ant ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity via miRNA targeting
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health